Continued Spending on Research and Development
First written in FY2017-Q1. 30 of 31 entries say "Restated". Latest entry: FY2026.
34 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥23,424 million.」
Full-year R&D expenses were ¥23.424 billion, up from ¥18.225 billion in the previous fiscal year, confirming continued expenditure on R&D. - FY2026-H1RestatedAnnual report
「Total research and development expenses for the interim consolidated accounting period were ¥11,195 million.」
As an ongoing investment in R&D, the company recorded ¥11.195 billion for the current interim consolidated accounting period. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥7,461 million.」
R&D expenses of ¥7.461 billion were disclosed for the interim consolidated accounting period, confirming continued spending on R&D. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the first 3 quarters of the fiscal year were ¥7.924 billion.」
Cumulative research and development expenses of ¥7,924 million for the first 3 quarters have been disclosed as ongoing spending on research and development activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the six-month period ended in the second quarter were ¥5,475 million.」
R&D expenses of ¥5.475 billion for the six months ended the second quarter were disclosed as ongoing expenditure on research and development activities. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal period were ¥2.662 billion.」
Research and development expenses of ¥2,662 million were disclosed for the cumulative first quarter, reflecting continued investment in R&D activities. - FY2023RestatedAnnual report
「The total amount of research and development expenses for the consolidated fiscal year was ¥11,031 million.」
Ongoing R&D expenditure was disclosed at ¥11,031 million for the full fiscal year, up from ¥10,278 million in the previous fiscal year. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the first 3 quarters of the current consolidated fiscal year were ¥7.829 billion.」
Research and development expenses of ¥7,829 million for the nine-month cumulative period have been disclosed as continuing expenditure on research and development activities. - FY2023-Q2RestatedAnnual report
「Research and development expenses for the six months ended 30 September amounted to ¥5.09 billion.」
As ongoing expenditure on R&D activities, R&D expenses of ¥5.09 billion for the cumulative second quarter were disclosed. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the first quarter cumulative consolidated period were ¥2,500 million.」
Research and development expenses of ¥2.5 billion for the cumulative first quarter were disclosed as continued spending on research and development activities. - FY2022RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥10.278 billion.」
Full-year research and development expenses of ¥10.278 billion were disclosed, confirming continued spending on research and development. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the nine-month period of the third quarter consolidated cumulative period were ¥7,170 million.」
Research and development expenses of ¥7.17 billion for the nine months ended the third quarter were disclosed, reaffirming continued spending on R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥4,706 million.」
R&D expenses of ¥4.706 billion for the cumulative second quarter were disclosed, reconfirming the company’s continued spending on R&D activities. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥2.305 billion.」
R&D expenses of ¥2,305 million for the cumulative first quarter were disclosed as ongoing expenditure on R&D activities. - FY2021RestatedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥10.155 billion.」
Full-year research and development expenses of ¥10.155 billion were disclosed, reconfirming the Company’s continued spending on research and development. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the first 3 quarters of the current consolidated fiscal year were ¥6.983 billion.」
Research and development expenses of ¥6,983 million for the third quarter cumulative period have been disclosed as continued spending on research and development activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥4.54 billion.」
R&D expenses of ¥4.540 billion for the cumulative second-quarter period were disclosed as ongoing expenditure on research and development activities. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the fiscal year were ¥2.333 billion.」
Continued spending on research and development activities of ¥2.333 billion was disclosed for the cumulative first quarter. - FY2020RestatedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥10,632 million.」
Full-year research and development expenses of ¥10.632 billion were disclosed, reconfirming the company's continued investment in R&D. - FY2020-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter ended ¥7.267 billion.」
Research and development expenses of ¥7.267 billion were disclosed, reaffirming continued spending on research and development activities. - FY2020-Q2RestatedAnnual report
「Total research and development expenses for the second quarter cumulative consolidated period were ¥4,960 million.」
R&D expenses of ¥4.96 billion for the cumulative second quarter were disclosed, reconfirming continued expenditure on R&D activities. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the three-month consolidated period under review were ¥2.508 billion.」
Research and development expenses of ¥2,508 million were disclosed, reaffirming continued spending on research and development activities. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter amounted to ¥6.890 billion.」
The company disclosed research and development expenses of ¥6.89 billion for the cumulative third quarter and reaffirmed its ongoing R&D spending. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter were ¥4,574 million.」
Research and development expenses of ¥4.574 billion for the cumulative second-quarter period were disclosed, reconfirming ongoing R&D spending. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the first 3 quarters of the current consolidated fiscal year were ¥2.375 billion.」
R&D expenses for the first-quarter cumulative period were disclosed at ¥2,375 million, reaffirming continued R&D spending. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the second quarter cumulative consolidated period were ¥4,353 million.」
Research and development expenses of ¥4,353 million have been disclosed for the cumulative second quarter as continuing expenditure on research and development activities. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the current first-quarter cumulative period were ¥1.97 billion.」
Research and development expenditure of ¥1,970 million was disclosed for the cumulative first quarter. - FY2017RestatedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥9.296 billion.」
Full-year research and development expenses of ¥9.296 billion were disclosed, reconfirming the Company’s continued spending on research and development. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the current third-quarter cumulative period were ¥6.236 billion.」
Continued spending on research and development activities was disclosed as ¥6,236 million. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the first 6 months of the current consolidated fiscal year were ¥4.253 billion.」
R&D expenses were disclosed at ¥4.253 billion on a cumulative second-quarter basis, reaffirming continued investment. - FY2017-Q1First statedAnnual report
「Total R&D expenses for the first quarter of the consolidated cumulative period were ¥2,203 million.」
Total R&D expenses for the quarter were disclosed.